Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas
Status:
Withdrawn
Trial end date:
2003-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can locate tumor cells and either kill
them or deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different ways to stop tumor cell from dividing so they stop growing or die.
Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of cetuximab plus gemcitabine in treating
patients who have locally advanced, metastatic, or recurrent cancer of the pancreas.